Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058761 | 0.98 | TYR (0.36) | TYRBCHEACHE | |
| SCHEMBL5053957 | 0.96 | TYR (0.34) | TYRBCHEACHE | |
| SCHEMBL5061159 | 0.92 | TYR (0.41) | TYRBCHEACHE | |
| SCHEMBL5053960 | 0.92 | TYR (0.39) | TYRBCHEACHE | |
| SCHEMBL5051777 | 0.90 | BCHE (0.41) | TYRBCHEACHE | |
| SCHEMBL5584056 | 0.71 | TYR (0.55) | TYRBCHEACHE | |
| SCHEMBL50738 | 0.70 | TYR (0.54) | TYRBCHEACHE | |
| SCHEMBL14230792 | 0.70 | MAPT (0.41) | — | |
| SCHEMBL4625644 | 0.70 | NR1H2 (0.35) | — | |
| SCHEMBL5677734 | 0.69 | LMNA (0.51) | TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401851-B8 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | FEBIT HOLDING GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1401851-B1 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | FEBIT BIOTECH GMBH (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-7355036-B2 | Two-stage protective groups for the synthesis of biopolymers | FEBIT AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | MR. CHRISTOPHER SEAGON, ESQ. (DE) | 2004-10-07 | — | — | US | disclosed |
| EP-1401851-A1 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | Febit AG (DE) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004510-A1 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | FEBIT AG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | CTRB2, OGG1, CPB2 | TYR 1545/4885BCHE 588/4885ACHE 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.